Guardant Health, Inc.

Guardant Health, Inc. is a leading precision oncology company dedicated to transforming cancer care through innovative liquid biopsy technology and advanced molecular diagnostics. Founded in 2012, the company's core mission is to conquer cancer with data, providing critical insights into the disease through blood and tissue tests, real-world data, and AI analytics to help patients live longer, healthier lives. Its corporate headquarters are located in Palo Alto, California.

Guardant Health offers a comprehensive portfolio of products and services across the cancer care continuum. Key offerings include the Guardant360 suite (Liquid, CDx, and Tissue) for comprehensive genomic profiling and treatment selection in advanced-stage cancer patients. The company also provides Guardant Reveal for molecular residual disease detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers, as well as therapy response monitoring. Additionally, Guardant Health developed Shield for colorectal cancer screening. The company extends its services to biopharmaceutical partners, offering research and development support.

Led by co-CEOs Helmy Eltoukhy and AmirAli Talasaz, Guardant Health continues to expand its market presence and product utility. In 2025, the company reported $982 million in revenue, representing 33% year-over-year growth, and projected 27-30% revenue growth for 2026. Recent strategic developments in 2026 include a multi-year collaboration with Nuvalent to develop companion diagnostics using the Guardant Infinity™ Platform and the launch of its Shield multi-cancer detection test in Asia through a partnership with Manulife. The company's Shield colon cancer test received FDA approval in 2024 and secured Medicare coverage by May 2025, further solidifying Guardant Health's position as a leader in precision oncology and liquid biopsy.

Latest updates

Guardant Health Partners with Nuvalent to Expand Companion Diagnostic Offerings

Event summary

  • Guardant Health (GH) and Nuvalent (NUVL) have entered a multi-year strategic collaboration.
  • The collaboration focuses on developing companion diagnostics (CDx) for Nuvalent’s oncology pipeline using Guardant’s liquid and tissue biopsy platform, Guardant Infinity™.
  • The agreement includes support for Nuvalent’s global clinical studies and potential commercialization across key markets.
  • Both companies are publicly traded on Nasdaq (GH and NUVL).

The big picture

This collaboration highlights the increasing convergence of diagnostics and therapeutics in oncology, driven by the demand for personalized medicine and biomarker-driven clinical trials. The partnership provides Nuvalent with a crucial diagnostic partner as it advances its kinase-targeted therapies, while Guardant expands its reach into the CDx market, a segment with significant growth potential. The deal underscores the strategic importance of liquid biopsy and tissue analysis in accelerating drug development and improving patient outcomes.

What we're watching

Commercialization
The success of this collaboration hinges on Nuvalent’s pipeline progressing to regulatory approval; the commercialization agreement suggests a shared revenue model, which could impact both companies' financials.
Regulatory Risk
The development of companion diagnostics is heavily reliant on regulatory acceptance and evolving guidelines, which could delay or impact the commercial viability of Nuvalent's therapies.
Platform Adoption
The extent to which Nuvalent integrates Guardant’s platform across its pipeline will indicate the broader appeal of Guardant Infinity™ for emerging targeted therapies.

Guardant Health to Present at Key Investor Conferences

Event summary

  • Guardant Health will participate in three investor conferences: BofA Securities Healthcare Conference (May 12), William Blair Growth Stock Conference (June 2), and Jefferies Global Healthcare Conference (June 3).
  • The BofA Securities conference features a fireside chat at 10:40 a.m. PT.
  • The William Blair conference includes a presentation at 9:20 a.m. CT.
  • The Jefferies conference will host a fireside chat at 11:05 a.m. ET.
  • Webcasts of the sessions will be available on Guardant Health’s investor relations website.

The big picture

Guardant Health’s participation in these conferences signals a continued effort to engage with the investment community and maintain visibility. These events offer a platform to communicate the company’s strategy and performance to a broad audience of institutional investors, which is crucial for maintaining a favorable valuation in a sector facing increasing scrutiny regarding clinical utility and reimbursement.

What we're watching

Investor Sentiment
The content and reception of these presentations will likely influence short-term stock performance, reflecting investor confidence in Guardant’s growth strategy and competitive positioning.
Growth Strategy
Management’s commentary on the conferences will provide insights into the company's plans for expanding its precision oncology offerings and penetrating new markets, which will reveal the viability of their long-term growth projections.
Competitive Landscape
The questions posed during the fireside chats and presentations may reveal how Guardant Health is addressing competitive pressures within the rapidly evolving precision oncology market.
CID: 3549